文献速递妇科

在临床前模型中用ICAM1抗体药物偶联物靶向治疗子宫内膜癌

Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates.
PubMed 文献 · Gynecol Oncol · 2025-03-26

本研究通过定量无偏生物信息学分析鉴定细胞间黏附分子-1(ICAM1)为子宫内膜癌(EC)潜在膜靶点,并开发ICAM1-MMAE与ICAM1-DXd两种抗体药物偶联物(ADC)。在体外和体内模型中,ICAM1 ADC较标准化疗显示更优抗肿瘤疗效,实现持续肿瘤消退且安全性良好,转录组分析提示ICAM1-DXd可激活肿瘤免疫。

要点

  • ICAM1在子宫内膜癌中显著过表达,被鉴定为ADC开发的潜在细胞膜靶点。
  • ICAM1-MMAE和ICAM1-DXd在临床前模型中较标准化疗显示更优抗肿瘤疗效,实现持续肿瘤消退。
  • ICAM1-DXd可激活肿瘤免疫,ICAM1 ADC在体外和体内均显示良好生物安全性。

核心结论

  • ICAM1被鉴定为子宫内膜癌ADC开发的有前景的细胞膜蛋白靶点。
  • 合成的ICAM1 ADC在体外和体内显示强效抗肿瘤活性、良好生物安全性及激活肿瘤免疫的能力。
  • 这些发现支持ICAM1 ADC作为治疗策略的潜力,并需进一步临床研究。

研究设计与样本

  • 通过定量无偏生物信息学分析鉴定ICAM1为潜在细胞膜靶点。
  • 将ICAM1单克隆抗体分别与微管抑制剂和DNA拓扑异构酶抑制剂偶联,开发ICAM1-MMAE和ICAM1-DXd两种ADC。
  • 在体外和体内模型中验证ICAM1 ADC的临床前疗效和生物安全性,并进行转录组分析。

主要发现

  • 定量流式筛选和生物信息学分析显示ICAM1在子宫内膜癌中显著过表达。
  • 在临床前模型中,ICAM1 ADC较标准化疗显示更优抗肿瘤疗效,在皮下和原位异种移植模型中实现持续肿瘤消退且安全性良好。
  • 转录组分析显示ICAM1-DXd强效激活肿瘤免疫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The incidence of mortality and morbidity from endometrial cancer (EC) is increasing annually, and there is a paucity of effective targeted therapies for the condition. Antibody-drug conjugates (ADCs) represent a promising approach to tumor-targeted therapy. In this study, we aim to identify a novel molecular target for the preclinical development of EC-targeted ADCs. METHODS: Through quantitative and unbiased bioinformatics analyses intercellular adhesion molecule-1 (ICAM1) was identified as a potential cell membrane target. Two ADCs, ICAM1-MMAE and ICAM1-DXd, were subsequently developed by conjugating ICAM1 monoclonal antibodies with microtubule inhibitors and DNA topoisomerase inhibitors, respectively. The preclinical efficacy and biosafety of these ICAM1 ADCs were validated in both in vitro and in vivo models. Furthermore, transcriptomic analysis was conducted to elucidate the therapeutic effects of the ICAM1 ADCs. RESULTS: Quantitative flow screening and bioinformatics analyses revealed significant overexpression of ICAM1 in EC. ICAM1-MMAE and ICAM1-DXd were developed using clinically effective linkers and payloads. In preclinical models, ICAM1 ADCs showed superior antitumor efficacy compared to standard chemotherapy, achieving sustained tumor regression with an excellent safety profile in both subcutaneous and orthotopic xenograft models. Transcriptomic analysis further revealed that ICAM1-DXd potently activated tumor immunity. CONCLUSIONS: ICAM1 was identified as a promising cell membrane protein target for ADC development in EC. As-synthesized ICAM1 ADCs demonstrated potent antitumor activity, favorable biosafety profiles in vitro and in vivo, and the ability to activate tumor immunity. These findings support the potential of ICAM1 ADCs as a therapeutic strategy and warrant further investigation in clinical studies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Xie H, Sun L, Yao S, et al. Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates. Gynecol Oncol. 2025. PMID: 40147093. doi:10.1016/j.ygyno.2025.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。